Cipla EU to invest EUR 3 million in Ethris to develop mRNA-based therapies
Cipla Limited announced that its wholly-owned subsidiary in United Kingdom, Cipla (EU) Limited will invest an additional EUR 3 million in Ethris GmbH (“Ethris”), a global leader in delivering mRNAs directly to the respiratory system. This additional investment through a convertible loan will accelerate Cipla’s partici…
